Greenwich LifeSciences Inc (NASDAQ: GLSI) is a clinical-stage biopharmaceutical company developing immunotherapy treatments for breast cancer. The company generates no product revenue, operating instead on capital raises to fund clinical development. Its lead candidate, GLSI-100 (GP2 + GM-CSF), is a peptide-based immunotherapy targeting HER2/neu-expressing breast cancer patients who are HLA-A*02 positive and have completed standard-of-care therapy. The compound was evaluated in a prospective, randomized, single-blinded, placebo-controlled Phase IIb clinical trial in high-risk, disease-free breast cancer patients. In the 96 HER2/neu 3+ overexpressor patients within the efficacy population, the trial observed a reduction in recurrence rates versus GM-CSF alone. GLSI-100 is designed to be administered following trastuzumab treatment and surgery. Snehal Patel serves as the company's attorney-in-fact for SEC filings, indicating a leadership role. The company is incorporated and files with the SEC as a clinical-stage entity with no disclosed commercial revenue as of the 10-K filed April 15, 2025.

Revenue model

No product revenue disclosed. The company is pre-commercial and funds operations through capital raises. All activity is directed toward clinical development and regulatory approval of GLSI-100.

Products and services

GLSI-100 (GP2 + GM-CSF): a peptide-based cancer immunotherapy targeting HER2/neu-expressing breast cancer in HLA-A*02 positive patients, evaluated in a Phase IIb clinical trial as an adjuvant treatment following standard-of-care therapy including trastuzumab and surgery.

Customers and end markets

End market is oncology, specifically breast cancer treatment. Target patient population is HER2/neu 1-3+ positive, HLA-A*02 positive, high-risk breast cancer patients who are disease-free after completing standard-of-care therapy. Intended prescribers include physicians and major cancer treatment centers.

Value-chain role

Clinical-stage drug developer. The company conducts clinical trials, prepares BLA submissions for FDA review, and relies on third-party manufacturers and clinical sites. It has not reached commercialization as of the 10-K filed April 15, 2025.

Geographic exposure

Primarily U.S.-focused clinical development. The filing references potential future international expansion and compliance obligations under FCPA, EU GDPR, and UK GDPR, but no current non-U.S. operations are described.

Source: SEC 10-K, filed 2025-04-15

Industry: Pharmaceutical Preparations Peers: Rezolute Inc Candel Therapeutics Inc Biostax Corp. INmune Bio Inc Syros Pharmaceuticals, Inc. Nuvectis Pharma Inc Praxis Precision Medicines Inc Shattuck Labs Inc XBiotech Inc